Modification of the structure of a metallopeptide: Synthesis and biological evaluation of 111in-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues

Journal of Medicinal Chemistry

Volumn 45, Issue 14, 2002, Pages 3048-3056

  Cheng, Zhen ^a   Chen, Jianqing ^b   Miao, Yubin ^a   Owen, Nellie K ^c   Quinn, Thomas P ^b   Jurisson, Silvia S ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERMEDIN DERIVATIVE; AMMONIUM ACETATE; BOVINE SERUM ALBUMIN; BUFFER; INDIUM; LYSINE; METAL COMPLEX; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DERIVATIZATION; DRUG TARGETING; DRUG TUMOR LEVEL; ISOTOPE LABELING; KIDNEY CLEARANCE; MELANOMA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PLASMA CLEARANCE; PROTEIN STRUCTURE; RADIOASSAY; RADIOISOTOPE DISTRIBUTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID STATE;

ALPHA-MSH; ANIMALS; BINDING, COMPETITIVE; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MELANOMA; MICE; MICE, INBRED C57BL; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0037019260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010408m     Document Type: Article

References (54)

1. Malignant melanoma: Prevention, early detection, and treatment in the 21st century
2. Cancer Statistics 1994
3. The march of melanoma
4. Preliminary observation of malignat melanoma therapy using radiolabeled alpha-methyltyrosine
5. 211At] Methylene blue for targeted radiotherapy of human melanoma xenografts: Dose fraction in the treatment of cutaneous tumors
6. Gallium-67 scanning for malignant melanoma
7. Oncological application of FDG PET imaging: Brain tumor, colorectal cancer lymphoma and melanoma
8. FDG-PET compared to conventional diagnostic methods in malignant melanoma
9. Intrapatient and interpatient comparison of tumor size and monoclonal antibody uptake in melanoma
10. Technetium-99m labeled monoclonal antibodies in the detection of metastatic melanoma
11. Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies
12. Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas
13. 131I labeled quinoline and tyrosine derivatives
14. 211At-Methylene blue for targeted radiotherapy of human melanoma xenografts: Treatment of micrometastases
15. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents
16. 125I-radiopharmaceuticals for diagnosis and treatment for malignant melanoma
17. Synthesis and evaluation of new iodine-125-radiopharmaceuticals as potential tracers for malignant melanoma
18. Radio-iodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure-affinity relationships, metabolic fate, and intracellular localization
19. A potential melanoma tracer: Synthesis, radiolabeling, and biodistribution in mice of a new nitridotechnetium Bis(aminothiol) derivative pharmacomodulated by a N-(diethylaniboethyl)benzamide
20. '3+1' mixed ligand oxotechnetium(V) complexes with affinity for melanoma: Synthesis and evaluation in vitro and in vivo
21. BisMSH-DTPA. A potential imaging agent for malignant melanoma
22. Imaging of metastatic melanoma utilizing a technetium-99m labeled RGD-containing synthetic peptide
23. Characterization of receptor for a-melanocyte stimulating hormone on human melanoma cells
24. Cloning and functional characterization of a family of receptors for the melanotropin peptides
25. Design, synthesis, and conformation of superpotent and prolonged acting melanotropin
26. 7] α-MSH: Discovery of a tripeptidyl agonist exhibiting sustained bioactivity
27. 4-Norleucine, 7-D-Phenylalaine-α-melanotropin-stimulating hormone: A highly potent a-melanotropin with ultra long biological activity
28. 2, on human melanocortin receptors
29. Metallopeptide approach to the design of biologically active ligands: Design of specific human neutrophil elastase inhibitors
30. Design of an artificial four-helix bundle metalloprotein via a noval ruthenium(II)-assisted self-assembly process
31. The reverse turn as a template for metal coordination
32. Design and characterization of α-melanotropin peptide analogues cyclized through rhenium and technetium metal coordination
33. 99mTc-labeled a-melano-tropin peptides
34. 99mTechnetium-labeled cyclic a-melanocyte-stimulating hormone peptide analogues
35. α-melanocyte-stimulating hormone peptide analogues labeled with technetium-99m and indium-111 for malignant melanoma targeting
36. 111In-DOTA-Rhenium cyclized a-MSH analog: A novel cyclic-peptide analogue with improved tumor targeting properties
37. The use of a chelating derivative of alpha-melanocyte stimulating hormone for the clinical imaging of malignant melanoma
38. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
39. Overcoming the nephrotoxicity of radio-metal-labeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry
40. IUPAC-IUB Commission of Biochemical Nomenclature (CBN) Symbols for Amino-Acid Derivatives and Peptides, Recommendations 1971
41. Technetium radiopharmaceuticals: Chemical characterization and tissue distribution of Tc-glucoheptonate using Tc-99m and carrier Tc-99
42. Synthesis and characterization of rhenium-complexed a-melanotropin analogues
43. Radio-receptor assay for α-MSH using mouse B16 melanoma cells
44. Intracellular metabolism of indium-111 DTPA labeled receptor targeted protein
45. 111In-DTPA-ε-lysine as the primary metabolic and excretory product
46. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo
47. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment
48. 111In-labeled DOTA-conjugated antibody fragments
49. Strategies to reduce renal radioactivity levels of antibody fragments
50. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
51. 111In-DTPA-conjugated peptides
52. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake